HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kosei Yasumoto Selected Research

Biomarkers (Surrogate Marker)

3/2011Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung.
7/2010Identification of a tumour associated antigen in lung cancer patients with asbestos exposure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kosei Yasumoto Research Topics

Disease

59Neoplasms (Cancer)
11/2020 - 01/2002
41Lung Neoplasms (Lung Cancer)
11/2020 - 03/2002
27Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2011 - 01/2002
11Neoplasm Metastasis (Metastasis)
08/2020 - 06/2002
10Adenocarcinoma
10/2011 - 09/2005
8Adenocarcinoma of Lung
11/2020 - 05/2006
8Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/2011 - 09/2005
6Carcinoma (Carcinomatosis)
01/2009 - 04/2003
5Colorectal Neoplasms (Colorectal Cancer)
08/2020 - 06/2002
4Melanoma (Melanoma, Malignant)
09/2009 - 07/2002
3Neoplasm Micrometastasis
12/2010 - 01/2002
3Lymphatic Metastasis
08/2009 - 10/2006
3Large Cell Carcinoma
03/2007 - 09/2005
3Esophageal Neoplasms (Esophageal Cancer)
09/2005 - 05/2005
2Testicular Neoplasms (Testicular Cancer)
01/2018 - 04/2010
2Fistula
09/2011 - 08/2010
2Myasthenia Gravis
09/2010 - 01/2009
2Malignant Mesothelioma
07/2010 - 07/2009
2Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
07/2009 - 09/2007
2Esophageal Squamous Cell Carcinoma
05/2009 - 07/2007
2Carcinogenesis
05/2006 - 07/2005
2Disease Progression
12/2005 - 01/2005
1Endometrial Neoplasms (Endometrial Cancer)
08/2020
1Neuroendocrine Carcinoma
08/2020
1Uterine Cervical Neoplasms (Cancer of the Cervix)
08/2020
1Uterine Neoplasms (Uterine Cancer)
08/2020
1Colonic Neoplasms (Colon Cancer)
04/2011
1Hyperthermia
03/2011

Drug/Important Bio-Agent (IBA)

18AntigensIBA
11/2020 - 03/2002
12ErbB Receptors (EGF Receptor)IBA
12/2011 - 01/2006
12Proteins (Proteins, Gene)FDA Link
12/2010 - 01/2002
8Gefitinib (Iressa)FDA Link
11/2010 - 01/2006
8Neoplasm Antigens (Tumor Antigens)IBA
01/2010 - 03/2002
6Peptides (Polypeptides)IBA
11/2020 - 04/2004
6ParaffinIBA
12/2010 - 10/2004
5Immunoglobulin G (IgG)IBA
07/2010 - 03/2002
5Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
05/2008 - 03/2003
4Tyrosine Kinase InhibitorsIBA
12/2011 - 12/2006
4Messenger RNA (mRNA)IBA
04/2011 - 08/2002
4Cisplatin (Platino)FDA LinkGeneric
11/2010 - 08/2002
4Biological ProductsIBA
08/2009 - 03/2005
3AsbestosIBA
07/2010 - 04/2003
3Indicators and Reagents (Reagents)IBA
05/2009 - 12/2004
3Estrogens (Estrogen)FDA Link
01/2009 - 07/2007
3CytokinesIBA
12/2007 - 02/2002
3CytochromesIBA
05/2007 - 12/2002
3HLA-A24 AntigenIBA
03/2007 - 05/2005
3Cytochrome P-450 CYP2E1 (CYP2E1)IBA
01/2007 - 12/2002
3Tumor Biomarkers (Tumor Markers)IBA
03/2005 - 01/2003
3Keratins (Keratin)IBA
07/2003 - 01/2002
2Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
12/2011 - 05/2010
2Estrogen Receptor betaIBA
03/2011 - 01/2009
2Estrogen ReceptorsIBA
03/2011 - 01/2009
2Biomarkers (Surrogate Marker)IBA
03/2011 - 07/2010
2Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2010 - 07/2007
2Paclitaxel (Taxol)FDA LinkGeneric
11/2010 - 07/2010
2Carboplatin (JM8)FDA LinkGeneric
11/2010 - 07/2010
2HLA Antigens (Human Leukocyte Antigens)IBA
10/2010 - 11/2007
2HLA-A Antigens (HLA-A)IBA
01/2010 - 03/2007
2VaccinesIBA
09/2009 - 05/2005
2AntibodiesIBA
07/2009 - 03/2002
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2009 - 01/2006
2Aromatase (CYP19)IBA
01/2009 - 05/2008
2EnzymesIBA
05/2008 - 02/2002
2Transcription Factors (Transcription Factor)IBA
12/2007 - 11/2004
2Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
05/2007 - 01/2007
2Cytochrome P-450 CYP1A1 (CYP1A1)IBA
01/2007 - 03/2003
2Cytochrome P-450 CYP3AIBA
01/2007 - 05/2005
2Carcinoembryonic AntigenIBA
10/2006 - 03/2005
2Complementary DNA (cDNA)IBA
09/2006 - 03/2002
2Histidine (L-Histidine)FDA Link
05/2006 - 05/2006
2PhytohemagglutininsIBA
05/2006 - 07/2005
2Amino AcidsFDA Link
05/2006 - 04/2004
1HLA-B15 AntigenIBA
11/2020
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
02/2012
1antigen CYFRA21.1IBA
10/2011
1Fibrin Tissue Adhesive (Fibrin Sealant)IBA
09/2011
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
04/2011
1Therapeutic UsesIBA
03/2011
1Cadherins (E-Cadherin)IBA
12/2010
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2010
1Vascular Endothelial Growth Factor CIBA
12/2010
1alpha Catenin (alpha E-Catenin)IBA
12/2010
1gamma Catenin (Plakoglobin)IBA
12/2010
1beta CateninIBA
12/2010
1GemcitabineFDA Link
11/2010

Therapy/Procedure

11Immunotherapy
01/2020 - 07/2002
9Therapeutics
08/2020 - 06/2002
7Drug Therapy (Chemotherapy)
08/2020 - 05/2005
4Adjuvant Chemotherapy
01/2013 - 03/2010
3Cell- and Tissue-Based Therapy (Cell Therapy)
08/2020 - 08/2020
3Radiotherapy
03/2011 - 01/2009
2Heterologous Transplantation (Xenotransplantation)
11/2020 - 07/2009
2Segmental Mastectomy (Lumpectomy)
01/2013 - 01/2011
2Ligation
08/2010 - 05/2008
2Lymph Node Excision (Lymph Node Dissection)
03/2010 - 06/2002
1Hepatectomy
01/2017
1Conservative Treatment
09/2011
1Thoracotomy
04/2011
1Aftercare (After-Treatment)
03/2011